Search

Displaying results 651 - 660 of 10000 in total
  1. Drug

    PX-478

    go.drugbank.com/drugs/DB06082
    Investigational

    PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. … PX-478 was effective in models of both non-small cell lung cancer and small cell lung cancer that express HIF-1 alpha.

  2. Drug

    Cobalamin

    go.drugbank.com/drugs/DB14098
    ApprovedInvestigational

    Mixtures: Vital-D Rx, NephPlex RxCategories: Vitamin B Complex, Vitamin B 12, biosynthesis
  3. Drug

    Dextran

    go.drugbank.com/drugs/DB09255
    ApprovedInvestigationalVet approved

    Dextran is a polysaccharide that differs from others in that its glucose units are joined together 1:6 glucoside links. … It is administered by intravenous infusion. Dextran 75 is a complex branched glucan with an average molecular weight 75000 Daltons.

    Mixtures: TEARS NATURALE II 1 MG/ML + 3 MG/ML GÖZ DAMLASI, SK Advanced Relief Eye DropsCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    GSK2256098

    go.drugbank.com/drugs/DB16106
    Investigational

    GSK2256098 is under investigation in clinical trial NCT02523014 (Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas).

    Categories: Heterocyclic Compounds, 1-Ring
  5. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986] … [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment

    Categories: MATE 1 Inhibitors, MATE 2 Inhibitors
  6. Drug

    Carbidopa

    go.drugbank.com/drugs/DB00190
    ApprovedInvestigational

    Carbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. … Due to its activity, carbidopa is always administered concomitantly with [levodopa].

    Synonyms: (S)-carbidopa, (S)-(−)-carbidopaMixtures: SR Tablet 50/200, CARBIDOPA X 25 MG Y LEVODOPA X 250 MG
  7. Drug

    TAK-448

    go.drugbank.com/drugs/DB11975
    Investigational

    TAK-448 has been used in trials studying the treatment of Prostate Cancer, Low Testosterone, Prostatic Neoplasms, and Hypogonadotropic Hypogonadism.

    Salts: TAK-448 acetate
  8. Drug

    Ensulizole

    go.drugbank.com/drugs/DB11115
    Approved

    Ensulizole, also known as 2-phenylbenzimidazole-5-sulfonic acid, is a water-soluble sunscreen agent that absorbs strongly at UV-B wavelengths. … It is commonly found in cosmetic products and sunscreen formulas in combination with other UV filter compounds due to its minimal protection against UV-A wavelengths.

    Mixtures: Cle De Peau Beaute Gentle Protective I, SK-II Facial Treatment UV Protection SPF 25Categories: Heterocyclic Compounds, 2-Ring
  9. Drug

    Iroxanadine

    go.drugbank.com/drugs/DB05444
    Experimental

    BRX-235 (iroxanadine) is a a novel small molecule synthesized by Biorex, Hungary that acts as a cardioprotective agent. … BRX-235 also causes translocation of calcium-dependent protein kinase C isoform to membranes.

    Categories: Heterocyclic Compounds, 1-Ring
  10. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a

    Categories: MATE 1 Inhibitors, P-glycoprotein inducersProducts: LORBRENA® 25 MG, LORBRENA® 100 MG